Gn-RH agonists and ovarian endometriosis

By Descamps P.   Lansac J.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 79, Iss. 2, 1998-08 ,pp. : 143-144

Elsevier

Access to resources Recommend Favorite

Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur(R)), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome

By Regidor P.-A.   Regidor M.   Kato K.   Bier U.W.   Buhler K.   Schindler A.E.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 73, Iss. 2, 1997-06 ,pp. : 153-160

Elsevier

Access to resources Recommend Favorite

Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, Cetrorelix, and GnRH agonists

By Nikolettos N.   Al-Hasani S.   Felberbaum R.   Demirel L.C.   Riethmuller-Winzen H.   Reissmann T.   Schopper B.   Sturm R.   Diedrich K.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 93, Iss. 1, 2000-11 ,pp. : 91-95

Elsevier

Access to resources Recommend Favorite

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

By Leondires M.P.   Escalpes M.   Segars J.H.   Scott R.T.   Miller B.T.  

Fertility and Sterility, Vol. 72, Iss. 6, 1999-12 ,pp. : 1018-1023

Elsevier

Access to resources Recommend Favorite

“Premature luteinization” in the era of GnRH analogue protocols: time to reconsider

By Younis Johnny  

Journal of Assisted Reproduction and Genetics, Vol. 28, Iss. 8, 2011-08 ,pp. : 689-692

Springer Publishing Company

Access to resources Recommend Favorite